National Medical Products Administration

$10+ Billion Acne Medication Markets by Therapeutic Class, Formulation, Type, Acne Type, and Distribution Channel - Global Opportunity Analysis and Forecasts to 2030 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, October 5, 2022

The "Acne Medication Market by Therapeutic Class, Formulation, Type, Acne Type, and Distribution Channel: Global Opportunity Analysis and Industry Forecast, 2022 - 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Acne Medication Market by Therapeutic Class, Formulation, Type, Acne Type, and Distribution Channel: Global Opportunity Analysis and Industry Forecast, 2022 - 2030" report has been added to ResearchAndMarkets.com's offering.
  • Hence, there is huge demand for topical as well as oral acne medication.
  • On the other hand, oral acne medication is relatively more effective where moderate to severe acne do not respond to topical agents.
  • Numerous factors such as changing hormone levels, rising teenage population, and growing adoption of skincare products significantly drive the growth of global acne medication market.

EQS-News: Vivoryon Therapeutics N.V.: Vivoryon Therapeutics N.V. Reports H1 2022 Financial Results and Highlights Operational Progress

Retrieved on: 
Friday, September 30, 2022

Firstly, we have been able to further de-risk clinical development of varoglutamstat with extremely encouraging safety results from our VIVIAD Phase 2b study.

Key Points: 
  • Firstly, we have been able to further de-risk clinical development of varoglutamstat with extremely encouraging safety results from our VIVIAD Phase 2b study.
  • Vivoryon presented detailed safety data from the VIVIAD study at the Alzheimers Association International Conference (AAIC) in San Diego (July 31 to August 4, 2022).
  • On June 22, 2022, Vivoryon held its Annual General Meeting where all voting items were approved with a large majority.
  • Condensed Statements of Profit or Loss and Other Comprehensive Income for the six months ended June 30, 2022 and 2021

JL Audio Announces MediaMaster® 105 and 105-HR Marine Source Units with DAB+ Tuner for European Market

Retrieved on: 
Thursday, September 29, 2022

DÜSSELDORF, Germany, Sept. 29, 2022 /PRNewswire/ -- JL Audio, manufacturer of high-performance marine audio systems, announced they will release an all-new MediaMaster® 105 and MediaMaster® 105-HR digital media source units. The MM105 and MM105-HR now feature digital radio tuners, both for HD Radio® and DAB+, making them equally capable in North America and Europe. The new source units also benefit from Bluetooth® 5.0 with Qualcomm's aptX™ technology, to reproduce music streamed from smartphones with the highest possible quality.

Key Points: 
  • DSSELDORF, Germany, Sept. 29, 2022 /PRNewswire/ -- JL Audio ,manufacturer of high-performance marine audio systems, announced they will release an all-new MediaMaster 105 and MediaMaster 105-HR digital media source units.
  • The new source units also benefit from Bluetooth 5.0 with Qualcomm's aptX technology, to reproduce music streamed from smartphones with the highest possible quality.
  • "The MM105 and MM105-HR are purpose-engineered to complement our premium amplifiers and loudspeakers to achieve the best marine audio experience.
  • The MediaMaster 105 and 105-HR source units emphasize audio performance, dispensing with on-board amplifiers in favor of an audiophile-quality preamp output architecture, ideal for use with JL Audio marine amplifiers.

Corvus Pharmaceuticals Announces Partner Angel Pharmaceuticals Received IND Approval for Phase 1/1b Clinical Trial of Mupadolimab (Anti-CD73) in China

Retrieved on: 
Monday, September 26, 2022

The study will be conducted by Angel Pharmaceuticals Ltd. (Angel Pharma), Corvus partner in China.

Key Points: 
  • The study will be conducted by Angel Pharmaceuticals Ltd. (Angel Pharma), Corvus partner in China.
  • Angel Pharma licensed the rights from Corvus to develop, manufacture and commercialize mupadolimab in greater China.
  • Our partnership with Angel Pharma continues to support the efficient development of our pipeline, said Richard A. Miller, M.D., co-founder, president and chief executive officer of Corvus.
  • Angel Pharma was launched through strategic collaboration with U.S.-based Corvus Pharmaceuticals and investments from Zhejiang Puissance Capital, Hisun Pharmaceuticals, Tigermed and funds associated with Betta Pharmaceuticals.

AIM Vaccine Announces Proposed Listing on the Main Board of SEHK

Retrieved on: 
Friday, September 23, 2022

According to CIC, AIM Vaccine is the only China-based vaccine player that has all five proven human vaccine platform technologies worldwide, namely bacterial vaccine technologies, viral vaccine technologies, genetically engineered vaccine technologies, combination vaccine technologies and mRNA vaccine technologies, with at least one approved product or one vaccine candidate at CTA or clinical stages under each platform.

Key Points: 
  • According to CIC, AIM Vaccine is the only China-based vaccine player that has all five proven human vaccine platform technologies worldwide, namely bacterial vaccine technologies, viral vaccine technologies, genetically engineered vaccine technologies, combination vaccine technologies and mRNA vaccine technologies, with at least one approved product or one vaccine candidate at CTA or clinical stages under each platform.
  • AIM Vaccine currently commercializes eight vaccine products against six disease areas, of which the HBV vaccines and human rabies vaccine are its market-leading key commercialized vaccine products.
  • AIM Vaccine acquired Rong'an Bio, AIM Honesty, AIM Kanghuai and AIM Weixin between 2015 and 2017, together with their vaccine products against human rabies, HBV, HAV, mumps and HFRS.
  • AIM Vaccine has leading scientists joining or collaborating with AIM Vaccine to support the Group's vaccine development and manufacturing.

PerkinElmer’s Oxford Immunotec Receives U.S. FDA Approval for T-Cell Select to Automate Clinically Superior Tuberculosis Detection

Retrieved on: 
Thursday, September 22, 2022

The T-Cell Select reagent kit allows for a more automated workflow, designed to reduce hands-on time for lab personnel and lower overall costs.

Key Points: 
  • The T-Cell Select reagent kit allows for a more automated workflow, designed to reduce hands-on time for lab personnel and lower overall costs.
  • The extended blood sample stability enables easy centralization of sample processing, which expands access to the T-SPOT.TB test and gives laboratories more flexibility with the potential for sample batching.
  • Automation closes the gap between ELISPOT and ELISA laboratory workflows, enabling more laboratories to offer the clinically superior T-SPOT.TB test to more physicians, said Phill Keefe, chief executive officer of PerkinElmers Oxford Immunotec division.
  • This results in the highest quality of care for the most vulnerable patients across the United States.

China CDE Grants CMG901 Breakthrough Therapy Designation for Claudin 18.2-Positive Advanced Gastric & Gastroesophageal Junction Cancer

Retrieved on: 
Thursday, September 22, 2022

CMG901 is a Claudin 18.2-targeted antibody-drug conjugate (ADC) developed for the treatment of Claudin 18.2-expressing solid tumors.

Key Points: 
  • CMG901 is a Claudin 18.2-targeted antibody-drug conjugate (ADC) developed for the treatment of Claudin 18.2-expressing solid tumors.
  • CDE's Breakthrough Therapy Designation is designed to expedite the clinical development of innovative drugs presenting significant clinical advantages.
  • [i] FDA granted CMG901 fast track designation for unresectable or metastatic gastric and gastroesophageal junction cancer which have relapsed and/or are refractory to approved therapies.
  • Accessed September 12, 2022. https://prn.to/3jXET0G
    [ii] CMG901 for the treatment of gastric cancer and gastroesophageal junction adenocarcinoma was granted the orphan-drug designation by the Food and Drug Administration of the United States.

China CDE Grants CMG901 Breakthrough Therapy Designation for Claudin 18.2-Positive Advanced Gastric & Gastroesophageal Junction Cancer

Retrieved on: 
Thursday, September 22, 2022

CMG901 is a Claudin 18.2-targeted antibody-drug conjugate (ADC) developed for the treatment of Claudin 18.2-expressing solid tumors.

Key Points: 
  • CMG901 is a Claudin 18.2-targeted antibody-drug conjugate (ADC) developed for the treatment of Claudin 18.2-expressing solid tumors.
  • CDE's Breakthrough Therapy Designation is designed to expedite the clinical development of innovative drugs presenting significant clinical advantages.
  • [i] FDA granted CMG901 fast track designation for unresectable or metastatic gastric and gastroesophageal junction cancer which have relapsed and/or are refractory to approved therapies.
  • Accessed September 12, 2022. https://prn.to/3jXET0G
    [ii] CMG901 for the treatment of gastric cancer and gastroesophageal junction adenocarcinoma was granted the orphan-drug designation by the Food and Drug Administration of the United States.

Nexalin Technology, Inc. Announces Closing of $9.6 Million Initial Public Offering

Retrieved on: 
Tuesday, September 20, 2022

HOUSTON, TEXAS, Sept. 20, 2022 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the Company or Nexalin) today announcedthe closing of its previously announced initial public offering of 2,315,000 units consisting of 2,315,000 shares of its common stock and 2,315,000 accompanying warrants to purchase 2,315,000 shares of common stock.

Key Points: 
  • HOUSTON, TEXAS, Sept. 20, 2022 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the Company or Nexalin) today announcedthe closing of its previously announced initial public offering of 2,315,000 units consisting of 2,315,000 shares of its common stock and 2,315,000 accompanying warrants to purchase 2,315,000 shares of common stock.
  • Maxim Group LLC acted as the sole book-running manager in connection with the offering.
  • This press release contains statements that constitute "forward-looking statements," including with respect to the Companys initial public offering.
  • No assurance can be given that the offering discussed above will be completed on the terms described, or at all.

Junshi Biosciences Receives NMPA Approval of sNDA for Toripalimab in Combination with Chemotherapy as First-Line Treatment for Advanced Non-squamous Non-Small Cell Lung Cancer

Retrieved on: 
Tuesday, September 20, 2022

This is the sixth indication approved for toripalimab in China and will bring more treatment options to Chinese patients with advanced NSCLC.

Key Points: 
  • This is the sixth indication approved for toripalimab in China and will bring more treatment options to Chinese patients with advanced NSCLC.
  • Professor Jie Wang from the Cancer Hospital, Chinese Academy of Medical Sciences elaborated on toripalimabs performance in clinical trials.
  • In China, the number of lung cancer patients is massive and so is the demand for treatment.
  • Junshi Biosciences has more than 3,100 employees in the United States (San Francisco and Maryland) and China (Shanghai, Suzhou, Beijing, Guangzhou, etc).